Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Equillium, Inc.NASDAQ: EQ
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.06, compared with -$0.24 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.38.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$0.19 (+51.3%) for the fiscal year ending Dec 2026, a step up from the -69.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.06-34.3% QoQ
- Last fiscal yearDec 2025
- -$0.39-69.6% YoY
- LTMMar 2026
- -$0.38+2.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +77.0% | +66.3% | -10.7 pp |
| 1 year | -69.6% | +51.3% | +120.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.39) USD
- Year-over-year change
- -69.6%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.39) | -69.6% |
| FY2024 | 2024-12-31 | (0.23) | +39.5% |
| FY2023 | 2023-12-31 | (0.38) | +88.1% |
| FY2022 | 2022-12-31 | (3.19) | -136.3% |
| FY2021 | 2021-12-31 | (1.35) | — |
EPS (Basic) vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 EPS (Basic) of -$0.38 is the 3rd highest of the 10 companies compared; the peer median is -$1.28.
- Its year-over-year change of +2.7% is the 6th highest of 10, against a peer median of +30.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $3.85 | +264.5% | — | |
| LTM Mar 2026 | -$0.29 | +30.0% | — | |
| LTM Mar 2026 | -$0.38 | +2.7% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$1.07 | -124.9% | — |
| LTM Mar 2026 | -$1.25 | -290.6% | — | |
| LTM Mar 2026 | -$1.28 | +38.9% | — | |
| LTM Mar 2026 | -$1.36 | -194.8% | — | |
| LTM Mar 2026 | -$2.47 | -183.1% | — | |
| LTM Mar 2026 | -$5.52 | +72.5% | — | |
| LTM Mar 2026 | -$37.6 | +62.6% | — | |
| Peer median (excluding EQ) | -$1.28 | +30.0% | — | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15.76M | 36.08M | 41.1M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 116K |
| Gross Profit | 0 | 15.76M | 36.08M | 41.1M | (116K) |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M |
| Selling, General & Admin | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M |
| Operating Expenses | 37.79M | 77.84M | 50.61M | 49.36M | 23.63M |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| EBITDA | (37.91M) | (61.26M) | (12.14M) | (7.57M) | (22.28M) |
| EBITDA Margin | — | -388.7% | -33.6% | -18.4% | — |
| Operating Income | (37.79M) | (62.08M) | (14.52M) | (8.27M) | (23.63M) |
| Operating Margin | — | -393.9% | -40.2% | -20.1% | — |
| Interest Income | 57K | 420K | 2.33M | 1.38M | 833K |
| Interest Expense | 1.07M | 1.05M | 491K | 0 | 0 |
| Other Income / Expenses | (1.27M) | (352K) | 1.77M | 563K | 1.24M |
| Income Before Tax | (39.05M) | (62.43M) | (12.76M) | (7.71M) | (22.4M) |
| Pre-Tax Margin | — | -396.1% | -35.3% | -18.8% | — |
| Income Tax Expense | 0 | 0 | 580K | 361K | 0 |
| Net Income | (38.98M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Net Margin | — | -396.1% | -37.0% | -19.6% | — |
| EPS (Basic) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| EPS (Diluted) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| Weighted Avg Shares | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
| Weighted Avg Shares (Diluted) | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.